A pilot dose-finding study of Terazosin in humans.
Jordan L SchultzPhillip E GanderCraig D WorkmanLaura L Boles PontoStephen CrossChristopher S NanceChristopher L GrothEric B TaylorSarah E ErnstJia XuErgun Y UcVincent A MagnottaMichael J WelshNandakumar S NarayananPublished in: medRxiv : the preprint server for health sciences (2024)
TZ at a dosage of 5 mg/day engages its metabolic targets effectively in both sexes without inducing significant adverse effects and provides a promising therapeutic avenue for mitigating energetic deficiencies. Further investigation via clinical trials to validate TZ's efficacy and safety in neurodegenerative (i.e., PD) contexts is warranted.